Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress.

ABSTRACT:

Background

As of 2019, the United States (US) was not on track to achieve targets for elimination, due to increasing incidence and treatment barriers. In 2020, the COVID-19 pandemic disrupted HCV services globally and in the US. As healthcare services normalize, there is an urgent need to reassess progress and evaluate scenarios that restore a pathway toward HCV elimination.

Methods

We updated a validated Markov model to estimate HCV-related morbidity and mortality in the US. Five scenarios were developed to bookend possible HCV outcomes in the wake of the pandemic. These included 1) return to pre-COVID-19 treatment forecasts; 2) achieve elimination targets through treatment and harm reduction; 3) long-term treatment disruptions; 4/5) achieve elimination targets through incr

SUBMITTER: Blach S 

PROVIDER: S-EPMC9674561 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature